WASHINGTON, March 31 (UPI) — The U.S. Food and Drug Administration has approved Asclera injections for the treatment of small types of varicose veins.
Although they usually occur in a person’s legs, the abnormally swollen or twisted veins can form in other parts of the body, the FDA said. Factors such as genetics, age, sex, pregnancy, obesity and prolonged periods of standing may increase the risk for varicose veins.
“Varicose veins are a common condition,” said Dr. Norman Stockbridge, director of the FDA’s Division of Cardiovascular and Renal Products. “Asclera (polidocanol) is indicated for the treatment of small types of varicose veins when the aim of treatment is to improve appearance.”
The FDA said Asclera is approved to close spider veins (tiny varicose veins less than 1 millimeter in diameter) and reticular veins (those that are 1 to 3 millimeters in diameter). Officials said Asclera acts by damaging the cell lining of blood vessels, causing the blood vessel to close, to eventually be replaced by other types of tissue.
Asclera is distributed by BioForm Medical Inc. of Franksville, Wis., and manufactured by Chemische Fabrik Kreussler & Co. of Wiesbaden, Germany.
Copyright 2010 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI’s prior written consent.